Imago BioSciences (Imago BioSciences) Revenue per Share : $0.00 (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Imago BioSciences Revenue per Share?

Imago BioSciences's revenue per share for the three months ended in Sep. 2022 was $0.00. Imago BioSciences's revenue per share for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Imago BioSciences's Revenue per Share or its related term are showing as below:

IMGO's 3-Year Revenue Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Imago BioSciences Revenue per Share Historical Data

The historical data trend for Imago BioSciences's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imago BioSciences Revenue per Share Chart

Imago BioSciences Annual Data

Trend

Dec19

Dec20

Dec21

Revenue per Share

Imago BioSciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Revenue per Share	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Imago BioSciences's Revenue per Share

For the Biotechnology subindustry, Imago BioSciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imago BioSciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imago BioSciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Imago BioSciences's PS Ratio falls into.

Imago BioSciences Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Imago BioSciences's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Revenue Per Share (A: Dec. 2021 )	=	Revenue (A: Dec. 2021 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2021 )
	=	0	/	15.696
	=	0.00

Imago BioSciences's Revenue Per Share for the quarter that ended in Sep. 2022 is calculated as

Revenue Per Share (Q: Sep. 2022 )	=	Revenue (Q: Sep. 2022 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2022 )
	=	0	/	33.766
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Imago BioSciences (NAS:IMGO) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Imago BioSciences Revenue per Share Related Terms

Thank you for viewing the detailed overview of Imago BioSciences's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Imago BioSciences (Imago BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imago BioSciences Inc (NAS:IMGO) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA, USA, 94080

Website

https://www.imagobio.com

Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).

Executives

Laura G. Eichorn	officer: Chief Operating Officer	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Michael Arenberg	officer: See Remarks	10260 BUBB ROAD, CUPERTINO CA 95014
Hugh Jr Rienhoff	director, officer: Chief Executive Officer	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Amy E. Tapper	officer: See Remarks	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Jennifer Peppe	officer: See Remarks	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Hsiangyi Chiang	officer: Senior Vice President Finance	C/O IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Ventures Iii Gp, L.p.	10 percent owner	C/O CLARUS VENTURES, 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Iii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Group Management L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings I/ii Gp L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings Ii L.p.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142